Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Atrial fibrillation (AF) involves 1% to 2% of the adult general population, a rate that increases to 15% in those 80 years and above.1 Because of the aging of the general population, this epidemic of AF is expected to increase over the next decades2–4 and to impose an increasing burden on the healthcare system because of the need for life-long care and pharmacological treatment. Identification of the mechanisms underlying AF represents an unmet need and a first step toward developing more effective preventive measures. Arterial hypertension (HT) is tightly associated with AF, as originally reported in the Framingham Heart Study5 and thereafter confirmed by several studies.6–13 HT is a major predictor of AF, and 50% to 90% of AF patients have HT. Accumulating evidences point to a role for the renin–angiotensin–aldosterone system (RAAS) in the pathophysiology of cardiac inflammation, fibrosis, and hypertrophy.14–17 Aldosterone not only exerts well-known pressor effects, but also promotes inflammation, myocardial necrosis, cardiac collagen deposition, fibrosis, and left ventricular hypertrophy (LVH).18,19 Accordingly, there is renewed interest in aldosterone as one of the major culprits leading to chamber remodeling and ultimately creating the stage for AF in hypertensive patients.15,17,20–25 The evidence supporting a role for aldosterone in AF was, however, derived from observational studies performed in patients with heart diseases that are known to cause AF. This leaves open the question of whether aldosterone triggers AF per se or only in the presence of structural heart disease. In recent years, 3 reviews examined the relation between aldosterone and AF: one focused on the antiarrhythmic potential of mineralocorticoid receptor (MR) antagonists in AF patients;26 another on the role of the MR in arrhythmias;27 and the last …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Telmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
The PICO strategy for the research question construction and evidence search
Santos, C. M. D. C., Pimenta, C. A. D. M., & Nobre, M. R. C. (2007) · Revista Latino-Americana de Enfermagem · doi:10.1590/s0104-11692007000300023 · Cited by 2,342 · cited 2×
“this aim, the literature was searched using the PICO strategy (Table S1 in the online-only Data Supplement).(29)”
MethodKannel, W. B., Wolf, P. A., Benjamin, E. J., & Levy, D. (1998) · The American Journal of Cardiology · doi:10.1016/s0002-9149(98)00583-9 · Cited by 2,033
Schnabel, R. B., Yin, X., Gona, P., Larson, M. G., Beiser, A. S., McManus, D. D., Newton-Cheh, C., Lubitz, S. A., Magnani, J. W., Ellinor, P. T., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61774-8 · Cited by 1,746
A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients
Rossi, G. P., Bernini, G., Caliumi, C., Desideri, G., Fabris, B., Ferri, C., Ganzaroli, C., Giacchetti, G., Letizia, C., Maccario, M., et al. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.07.059 · Cited by 1,467
Self-citationWachtell, K., Lehto, M., Gerdts, E., Olsen, M. H., Hornestam, B., Dahlöf, B., Ibsen, H., Julius, S., Kjeldsen, S. E., Lindholm, L. H., et al. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.10.068 · Cited by 826
Healey, J. S., Baranchuk, A., Crystal, E., Morillo, C. A., Garfinkle, M., Yusuf, S., & Connolly, S. J. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2004.11.070 · Cited by 822
Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study
Stewart, S., Hart, C. L., Hole, D. J., & McMurray, J. J. V. (2001) · Heart · doi:10.1136/heart.86.5.516 · Cited by 661
Eplerenone and Atrial Fibrillation in Mild Systolic Heart Failure
Swedberg, K., Zannad, F., McMurray, J. J. V., Krum, H., van Veldhuisen, D. J., Shi, H., Vincent, J., & Pitt, B. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.11.063 · Cited by 313
Cited by
Hundemer, G. L., Curhan, G. C., Yozamp, N., Wang, M., & Vaidya, A. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30367-4 · Cited by 677
Atrial Fibrillation and Hypertension
Dzeshka, M. S., Shantsila, A., Shantsila, E., & Lip, G. Y. H. (2017) · Hypertension · doi:10.1161/hypertensionaha.117.08934 · Cited by 148
Gorenek, B., Boriani, G., Dan, G.-A., Fauchier, L., Fenelon, G., Huang, H., Kudaiberdieva, G., Lip, G. Y. H., Mahajan, R., Potpara, T., et al. (2018) · EP Europace · doi:10.1093/europace/euy051 · Cited by 43
Metadata
- Authors
- Seccia, T. M., Caroccia, B., Adler, G. K., Maiolino, G., Cesari, M., & Rossi, G. P.
- Venue
- Hypertension
- Published
- 2017-04
- Volume
- 69
- Issue
- 4
- Pages
- 545-550
- ISSN
- 0194-911X (ISSN-L)
- 1524-4563
- OpenAlex
- W2592956313
- Cited by
- 66
- References
- 9
- FWCI
- 6.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble. https://app.cochat.ai/papers/10.1161/hypertensionaha.116.08956
- The paper
- Seccia, T. M., Caroccia, B., Adler, G. K., Maiolino, G., Cesari, M., & Rossi, G. P. (2017). Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble. Hypertension. https://doi.org/10.1161/hypertensionaha.116.08956
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.